These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 21414214)

  • 21. [Relationship between EGFR and K-ras mutations and clinicopathological characteristics and response to erlotinib treatment in 301 Chinese patients with non-small cell lung cancer].
    Sun LN; Luan HL; Zang FL; Wang M; Dong N; Guo Y; Sun BC; Zhan ZL
    Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):667-70. PubMed ID: 21122380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases.
    Mak KS; Gainor JF; Niemierko A; Oh KS; Willers H; Choi NC; Loeffler JS; Sequist LV; Shaw AT; Shih HA
    Neuro Oncol; 2015 Feb; 17(2):296-302. PubMed ID: 25053852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical Research of EGFR and KRAS Mutation in Fine Needle Aspiration Cytology Specimens of Non-small Cell Lung Carcinoma].
    Zhang Z; Wu X; Ying J; Li J; Qiu T; Guo H; Zhao H; Shan L; Ling Y
    Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):199-205. PubMed ID: 25936883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
    Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
    J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
    Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
    Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-analysis of epidermal growth factor receptor and KRAS gene status between primary and corresponding metastatic tumours of non-small cell lung cancer.
    Wang S; Wang Z
    Clin Oncol (R Coll Radiol); 2015 Jan; 27(1):30-9. PubMed ID: 25445553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations.
    Ludovini V; Bianconi F; Pistola L; Pistola V; Chiari R; Colella R; Bellezza G; Tofanetti FR; Siggillino A; Baldelli E; Flacco A; Giuffrida D; Sidoni A; Crinò L
    Cancer Chemother Pharmacol; 2012 May; 69(5):1289-99. PubMed ID: 22302407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
    Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
    Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies.
    Bauml J; Mick R; Zhang Y; Watt CD; Vachani A; Aggarwal C; Evans T; Langer C
    Clin Lung Cancer; 2013 Sep; 14(5):581-91. PubMed ID: 23827517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.
    Sun JM; Hwang DW; Ahn JS; Ahn MJ; Park K
    PLoS One; 2013; 8(5):e64816. PubMed ID: 23724098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy.
    Fiala O; Pesek M; Finek J; Benesova L; Bortlicek Z; Minarik M
    Anticancer Res; 2013 Apr; 33(4):1705-11. PubMed ID: 23564819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased detection rates of EGFR and KRAS mutations in NSCLC specimens with low tumour cell content by 454 deep sequencing.
    Moskalev EA; Stöhr R; Rieker R; Hebele S; Fuchs F; Sirbu H; Mastitsky SE; Boltze C; König H; Agaimy A; Hartmann A; Haller F
    Virchows Arch; 2013 Apr; 462(4):409-19. PubMed ID: 23468066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EGFR mutations, gene amplification, and protein expression and KRAS mutations in primary and metastatic tumors of nonsmall cell lung cancers and their clinical implications: a meta-analysis.
    Han C; Ma J; Zhao J; Zhou Y; Jing W; Zou H
    Cancer Invest; 2011 Nov; 29(9):626-34. PubMed ID: 22011285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer.
    Gow CH; Chang YL; Hsu YC; Tsai MF; Wu CT; Yu CJ; Yang CH; Lee YC; Yang PC; Shih JY
    Ann Oncol; 2009 Apr; 20(4):696-702. PubMed ID: 19088172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
    Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
    Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological features and EGFR gene mutation status in elderly patients with resected non-small-cell lung cancer.
    Nishii T; Yokose T; Miyagi Y; Daigo Y; Ito H; Isaka T; Imai K; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Tsuboi M; Nakayama H; Masuda M
    BMC Cancer; 2014 Aug; 14():610. PubMed ID: 25152277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
    Caicedo C; Garcia-Velloso MJ; Lozano MD; Labiano T; Vigil Diaz C; Lopez-Picazo JM; Gurpide A; Zulueta JJ; Richter Echevarria JA; Perez Gracia JL
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients.
    Ragusa M; Vannucci J; Ludovini V; Bianconi F; Treggiari S; Tofanetti FR; Flacco A; Colella R; Sidoni A; Crinò L; Puma F
    Am J Clin Oncol; 2014 Aug; 37(4):343-9. PubMed ID: 23357969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EGFR and KRAS mutations and altered c-Met gene copy numbers in primary non-small cell lung cancer and associated stage N2 lymph node-metastasis.
    Han CB; Ma JT; Li F; Zhao JZ; Jing W; Zhou Y; Zou HW
    Cancer Lett; 2012 Jan; 314(1):63-72. PubMed ID: 21982684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.